Navigation Links
Northern California Foot and Ankle Center Santa Rosa Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Research Trial
Date:3/12/2008

SANTA ROSA, Calif., March 12 /PRNewswire/ -- Northern California Foot and Ankle Center Santa Rosa today announced it is recruiting patients with lower extremity diabetic foot ulcers to participate in the MATRIX clinical research trial. The MATRIX trial will study the effects of Excellarate(TM) (GAM501) (Ad5PDGF-B/bovine Type I collagen gel) for the potential treatment of patients with neuropathic non-healing diabetic foot ulcers. Excellarate is an investigational product designed to stimulate the process of wound healing.

The MATRIX (A Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers in the Lower Extremities) trial is a randomized, double-blind, placebo-controlled, comparator arm (standard of care) safety and efficacy study to evaluate GAM501 (Ad5PDGF-B/bovine type I collagen gel) that is topically administered once or twice over the course of the study. The primary endpoint will be the effect of Excellarate on the incidence of complete ulcer closure at 12 weeks or earlier.

"The Excellarate topical gel using Gene Activated Matrix (GAM) technology is designed to provide localized and sustained cellular release of platelet-derived growth factor-BB protein (PDGF-BB). Sustained delivery of PDGF-BB directly at the wound site is believed to stimulate angiogenesis and granulation tissue formation through the recruitment and proliferation of chemotactic cells such as monocytes, fibroblasts, and endothelial cells, which are necessary for the stimulation of a variety of wound healing processes," stated Walter F. D'Costa DPM, CWS, FCCWS, and a trial investigator.

There are currently more than 20 million Americans who have diabetes and this number is expected to double by the year 2030. Many diabetic patients suffer from peripheral neuropathy, or a loss of feeling in their feet, that puts them at increased risk of foot ulceration. Over 850,000 chronic diabetic ulcers are diagnosed in the U.S. each year. Patients with non-healing ulcers are more susceptible to infections that may lead to amputation of the affected foot or leg.

Northern California Foot and Ankle Center Santa Rosa is among an estimated 25 sites participating in the MATRIX trial. The trial is expected to enroll 210 patients nationwide. Prospective participants can call (707) 544-3337 for more information about the study and eligibility.

About Northern California Foot and Ankle Center Santa Rosa

Northern California Foot and Ankle Center Santa Rosa has been involved in the treatment of the Diabetic Extremity Wounds since 1980. Dr. Walter D'Costa was the past President of the Redwood Podiatric Medical Association and has a teaching appointment with the University of California San Francisco -- Santa Rosa Campus. He has lectured on the Diabetic Foot extensively over the years. He is the founder of the Department of Podiatric Medicine at Sutter Hospital and has served as Chair of the Department of Podiatric Medicine and Surgery and Credentials Committee. He was Chief of Staff Elect at Sutter Medical Center Santa Rosa.


'/>"/>
SOURCE Northern California Foot and Ankle Center Santa Rosa
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Saving Lives of California Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment
2. California Legislature Passes Historic HIV Testing Bill (AB 682); AHF Urges Governor to Sign Crucial Lifesaving Legislation
3. Veto of Californias Condoms in Prisons Bill: "Politics Over Public Health," Says AHF
4. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
5. New Conflict of Interest Violations Revealed at California Stem Cell Institute
6. Associated Foot & Ankle Specialists Enrolling Patients With Chronic Diabetic Foot Ulcers for MATRIX Clinical Trial
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
11. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... -- Several leading Alzheimer,s disease experts will participate in ... 11 a.m. EST on December 6 in advance of ... Alzheimer,s Disease (CTAD). The program will include discussions on ... targets that address deficient glucose metabolism observed in Alzheimer,s ... another therapy targeting the amyloid hypothesis, now more than ...
(Date:12/5/2016)... and BOCA RATON, Fla. ... Florida Institute for the Commercialization of Public Research ... has finalized a funding agreement SegAna, LLC, an ... developed at University of Central Florida. The Florida ... research, and bridges early funding gaps for companies ...
(Date:12/5/2016)... , December 5, 2016 According to a ... modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free composites), Application ... MarketsandMarkets, the market is projected to reach USD 779.8 Million by ... of 13.5% during the forecast period of 2016 to 2021. ... ...
Breaking Medicine Technology:
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... Dr. Barry ... Avenue Cosmetic Plastic Surgery, who recently participated in the 36th Annual Cutting Edge Aesthetic ... of the newest techniques for getting that perfect, yet natural-looking, nose. Dr. Weintraub, who ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... ("GPP") portfolio company, today announced it has acquired the assets of Frankfurt, ... previously a subsidiary of Chiltern International and focuses on clinical trial drug ...
(Date:12/5/2016)... ... ... has joined the Retina Group of New York (RGONY) specializing in uveitis and ... and has been providing tertiary medical and surgical retinal care on Long Island for over ... peers. Growing up in a family of doctors, Dr. Shah emulated the role of ...
(Date:12/5/2016)... ... December 05, 2016 , ... Houston ... 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging Medicine European ... European Congress (AMEC) brings together the industry’s leading scientific experts, speakers, clinicians, ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... Swirl: A Wine Tasting Event in New York City, with long-time partners The ...
Breaking Medicine News(10 mins):